One turnaround stock I’d sell to buy Tullow Oil plc

Roland Head explains why Tullow Oil plc (LON:TLW) could be a bargain at its current level.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m looking at two turnaround stocks at different stages of their recovery.

I’ve recently turned positive on oil group Tullow Oil (LSE: TLW), as I’ll explain later in this piece. But I’m not sure if today’s second stock — information management software group Idox (LSE: IDOX) — has reached the end of the troubles which caused its shares to crash last year.

The market likes it

The market has given a warm reception to today’s delayed full-year figures from Idox. At the time of writing, the shares are up 10% to 37p.

Today’s gains have come despite news that the firm’s adjusted profits for the year missed the revised guidance provided in December’s profit warning. Adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) fell by 14% to £18.3m last year, below December’s revised forecast of £20m.

The group originally expected to report EBITDA of £27.2m last year. A cocktail of problems prevented this, including delayed contracts, incorrect revenue recognition and complications arising from last year’s acquisition of healthcare software firm 6PM.

Look forward, not back

Investors appear to be comfortable that interim chief executive (and former CEO) Richard Kellett-Clarke has resolved these issues. To some extent I agree. But I’m not completely convinced.

Although the group announced several contract wins today, Mr Kellett-Clarke warned that plans for “a change in product pricing” and “a focus on cash conversion” will initially depress revenue. He plans £7m of cost-cutting to help rebuild margins, but it’s not clear to me how quickly these benefits will come through.

I’m also concerned that the 6PM acquisition could cause further problems. The group’s auditors issued what’s known as a qualified opinion on today’s results. Their view appears to be that 6PM’s record-keeping prior to the Idox acquisition was so poor, they couldn’t be sure that some of its figures were correct.

Although Idox looks cheap on about 7 times 2018 forecast earnings, I think these forecasts are likely to be revised following today’s results. I also think the 6PM acquisition could cause further headaches. I will be staying clear for now.

I was impressed by these figures

As a contrast, the recent 2017 results from Tullow Oil were strong enough to persuade me to take a positive view on this stock.

The group’s net debt fell from $4.8bn to $3.5bn, thanks to $721m of proceeds from a rights issue, lower spending and improved cash flow. The group also managed to refinance much of its debt, providing security about future repayment schedules.

All of these factors were largely predictable, but I wanted to see concrete evidence of progress before considering an investment. Luckily the stock is now on sale at a price that’s 22% lower than one year ago, when the risks were considerably higher in my view.

Why I’d buy

Although Tullow’s remaining net debt of $3.5bn is still equivalent to a chunky 2.6 times EBITDA, last year’s free cash flow of $543m gives me confidence that this figure should continue to fall in 2018.

This free cash flow gives the stock a trailing price/free cash flow ratio of 6.5, which is very cheap. Although spending will be higher this year, reducing surplus cash, I still expect the firm to be strongly cash generative.

As net debt continues to fall and profits gradually recover, I’d believe Tullow shares could deliver attractive gains.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »